HPK1 inhibitors target a T cell-intrinsic negative regulator for immuno-oncology. Synergy with checkpoint inhibitors, kinase-dead mouse validation, and emerging clinical potential.
WEE1 and CHK1 inhibitors exploit cell cycle checkpoint defects in cancer. Synthetic lethality with p53 loss, mitotic catastrophe, and checkpoint control mechanisms.
SHP2 inhibitors TNO155 and RMC-4550 target the first druggable phosphatase in cancer. Allosteric mechanism, synergy with KRAS G12C inhibitors, and clinical development.
Glutaminase inhibitors CB-839 and BPTES targeting cancer’s glutamine addiction. How GLS1 inhibition disrupts cancer cell biosynthesis and metabolism.
IDH1 and IDH2 inhibitors targeting oncometabolite 2-hydroxyglutarate. Ivosidenib, enasidenib, and their role in glioma and AML research and therapy.
Honest assessment of curcumin and synthetic analogs like EF24 and FLLL32. Why natural curcumin has limited bioavailability and how research-grade derivatives improve selectivity.
Natural product kinase inhibitors from staurosporine to midostaurin. How evolution inspired drug discovery and why natural products remain essential research tools.
Explore ROS1 inhibitors from crizotinib to next-generation compounds like entrectinib and lorlatinib. Learn how researchers select ROS1 tools and understand resistance mechanisms.
Master a year-round plant disease testing calendar for Canadian greenhouses. Learn what to test each season, from spring transplant screening to winter propagule evaluation.
Discover how AmplifyRP isothermal amplification provides PCR-level sensitivity for plant pathogen detection without a thermocycler. Learn RPA technology and real-world greenhouse applications.
